| pubmed-article:15195482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0085253 | lld:lifeskim |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:15195482 | lifeskim:mentions | umls-concept:C0868928 | lld:lifeskim |
| pubmed-article:15195482 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15195482 | pubmed:dateCreated | 2004-6-15 | lld:pubmed |
| pubmed-article:15195482 | pubmed:abstractText | Adult Still's disease is a systemic inflammatory disorder of unknown etiology. First-line treatment for Still's disease includes nonsteroidal anti-inflammatory drugs and corticosteroids. In refractory cases o when the dose of corticosteroid is unacceptably high, other disease modifying antirheumatic drugs have been used. But recent study showed the efficacy anti-TNF therapy in adult Sill's disease refractory to conventional therapy. We report a favourable response to infliximab in two patients who has proved resistant to conventional therapy. | lld:pubmed |
| pubmed-article:15195482 | pubmed:language | spa | lld:pubmed |
| pubmed-article:15195482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15195482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15195482 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15195482 | pubmed:issn | 0212-7199 | lld:pubmed |
| pubmed-article:15195482 | pubmed:author | pubmed-author:Martín-MolaEE | lld:pubmed |
| pubmed-article:15195482 | pubmed:author | pubmed-author:de Miguel... | lld:pubmed |
| pubmed-article:15195482 | pubmed:author | pubmed-author:Cobo IbáñezTT | lld:pubmed |
| pubmed-article:15195482 | pubmed:author | pubmed-author:Bonilla... | lld:pubmed |
| pubmed-article:15195482 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15195482 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:15195482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15195482 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15195482 | pubmed:pagination | 23-6 | lld:pubmed |
| pubmed-article:15195482 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:meshHeading | pubmed-meshheading:15195482... | lld:pubmed |
| pubmed-article:15195482 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15195482 | pubmed:articleTitle | [Infliximab (anti-TNF-alpha) treatment in patients with adult Still's disease. Experience in 2 cases]. | lld:pubmed |
| pubmed-article:15195482 | pubmed:affiliation | Servicio de Reumatología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid. magebo@eresmas.com | lld:pubmed |
| pubmed-article:15195482 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15195482 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:15195482 | pubmed:publicationType | Case Reports | lld:pubmed |
